Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing



Similar documents
Perioperative Cardiac Evaluation

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Pre-Operative Cardiac Evaluation Kalpana Jain, MD

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

CARDIAC RISKS OF NON CARDIAC SURGERY

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

Listen to your heart: Good Cardiovascular Health for Life

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

How to Keep Your Surgeon Out of Trouble: Perioperative Medicine: Risk Stratification

Perioperative myocardial infarction. for Perioperative Cardiac Events. Paul Lee, M.D., M.P.H. Perioperative Cardiac Risk in Non-Cardiac Surgery

Efficient Evaluation of Chest Pain

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

ECG may be indicated for patients with cardiovascular risk factors

Main Effect of Screening for Coronary Artery Disease Using CT

Atrial Fibrillation Management Across the Spectrum of Illness

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code )

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Atrial Fibrillation The Basics

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Geriatric Cardiology: Challenges and Strategies

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Perioperative management of the

PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care

Redefining the NSTEACS pathway in London

Atrial Fibrillation An update on diagnosis and management

STROKE PREVENTION IN ATRIAL FIBRILLATION

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie 1

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

on behalf of the AUGMENT-HF Investigators

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Cilostazol versus Clopidogrel after Coronary Stenting

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Nursing Care and Considerations for Patients with Atrial Fibrillation. Kris Kinghorn RN, MSN, ANP-BC

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Non Invasive Testing for CAD

9/6/ % 25% 25% 25%

CARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

Duration of Dual Antiplatelet Therapy After Coronary Stenting

ACC/AHA Pocket Guidelines

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015

Section 8: Clinical Exercise Testing. a maximal GXT?

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

INTRODUCTION TO EECP THERAPY

The Role Of Early Stress Testing In Assessing Low Risk Chest Pain Patients Admitted Through The Emergency Department

Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

Roux-en-Y Gastric Bypass

Presenter Disclosure Information

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

In patients undergoing noncardiac surgery, preoperative

ABOUT XARELTO CLINICAL STUDIES

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

How do you decide on rate versus rhythm control?

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

06 Validation of risk prediction model

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Ischemic Heart Disease: Angina Pectoris

Ngaire has Palpitations

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter

Anticoagulation at the end of life. Rhona Maclean

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

New Anticoagulants and GI bleeding

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Anticoagulation Therapy Update

James F. Kravec, M.D., F.A.C.P

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Antiplatelet and Antithrombotics From clinical trials to guidelines

Transcription:

Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing

Outline The coming crush A practical approach to clinical risk assessment Classic approach to clinical assessment Surgical risk assessment Risk intervention strategies and effect Summary

Case 54 yo African American man with: Hx CEA Hx Subclavian stenosis HTN DM Pre-Op eval Fem Pop

CASE Cath 3VD with 75 LM and 100% RCA EF normal CABG Successful Fem Pop 3 mo later.

Epidemiology 27 million patients have surgery each year 30% of patients have coronary disease or risk factors for CAD. 1 million perioperative complications 20 billion dollar cost

Epidemiology Bigger problem in the future 37 million surgeries per year within the next few decades 40% of patients with or at risk for CAD Many more billions in cost

Approaches for dealing with the Test no one problem Test every one Develop methods to select those who will benefit from testing

Dealing with the Problem Identify the risks Patient centered Procedure centered Intervene on the risks How Mortality/Morbidity cost Monetary cost

Clinical Risks - Goldman Criteria Risk is indexed into 4 classes Score Event Free Morbidity Mortality Class I 0-5 99% 0.7% 0.3% Class II 6-12 93% 5% 1.6% Class III 13-25 86% 11% 3 % Class IV > 26 22% 22% 56% NEJM 297:845;1977

Clinical Risks - Goldman Criteria Factor Score MI within 6 mo 10 S3 gallop or JVD 11 Rhythm other than sinus 7 > 5 PVC s per min 7 Aortic Stenosis 3 Intraperitoneal, thoracic or aortic 3 Emergent operation 4 Age > 70 5 Bun > 50 or Cr > 3 3 NEJM 297:845;1977

Lee index

Lee index and long term mortality Lee index collected on 711 consecutive subjects undergoing vascular surgery 149 deaths at 3 year follow-up Late mortality predicted with hazard ratio of 2.1 to 3.2 for Lee index values of 1 to >3 The American Journal of Medicine (2009) 122, 559-565

ACC/AHA Evaluation and Care Algorithm 2007

Clinical Predictors of Risk Major Unstable coronary syndromes Acute or recent MI* with evidence of important ischemic risk by clinical symptoms or noninvasive study Unstable or severe angina (Canadian class III or IV) Decompensated heart failure Significant arrhythmias High-grade atrioventricular block Symptomatic ventricular arrhythmias in the presence of underlying heart disease Supraventricular arrhythmias with uncontrolled ventricular rate Severe valvular disease

Clinical Predictors of Risk Intermediate Mild angina pectoris (Canadian class I or II) Previous MI by history or pathologic Q waves Compensated or prior heart failure Diabetes mellitus (particularly insulin-dependent) Renal insufficiency Minor Advanced age Abnormal ECG (left ventricular hypertrophy, left bundle-branch block, ST-T abnormalities) Rhythm other than sinus (e.g., atrial fibrillation) Low functional capacity (e.g., inability to climb one flight of stairs with a bag of groceries) History of stroke Uncontrolled systemic hypertension

Clinical Risk Factors - Is disease present? Special low risk categories CABG w/in 5 years w/out sx Operative mortality for vascular surgery only 1.5% Mortality in patients w/o disease 1.3% Ann Vasc Surg 1:616;1987 Negative ETT or Cath w/in 2 years w/out new sx

Clinical Risk Factors Is disease present? Ischemic Threshold What brings on symptoms? rest or low levels of activity = high risk Unstable coronary syndromes are highest risk Canadian class III or IV are high risk stable angina or history of MI without current symptoms and good functional status = low risk At least a flight of stairs with a bag of groceries

Functional Status

Functional status Excellent Good Moderate Poor > 10 METS 7-10 METS 4-7 METS < 4 METS

Functional Status 600 Consecutive patients < 4 METS Increased risk even after adjustment for baseline characteristics Outcomes inversely related to Number of blocks able to walk Number of flights of stairs can climb Reilly et al Arch Int Med 1999,159:2185

Functional status Evidence limitations The positive predictive value of poor exercise capacity in the perioperative setting is only 10%, with a negative predictive value of 95%. If patients reduce exertion because of cardiac symptoms but still meet a 4-MET threshold, clinicians will underestimate risk. Conversely, noncardiac functional limitations (eg, knee or back pain) may falsely overestimate cardiac risk.

ACC/AHA Evaluation and Care Algorithm 2007

Risk - Procedural Risk Emergent procedures Elective categories High - (cardiac risk > 5%) Medium - (cardiac risk < 5%) Low - (cardiac risk < 1%)

Surgical Risk Categories

Elective Surgical Procedures and CV High (>5%) Risk Medium (<5%) Low (< 1%) Major vascular CEA Endoscopic Peripheral vascular Orthopedic Superficial Prolonged Surgery Abdominal or Thoracic Cataract Large fluid or blood shifts Prostate Breast

Emergent Procedures Cardiac risk is at least 2-5 times that of elective procedures Ruptured AAA mortality 42% Urgent symptomatic AAA repair mortality 19% Elective AAA repair mortality 3.5% Consultants role is to address modifiable risks.

Decision Analysis Table Clinical risk Score Low Med High Surgical Procedure Risk Low Med High Surgery Surgery Surgery Surgery Surgery* Stratify Surgery Stratify Stratify

ACC/AHA Evaluation and Care Algorithm 2007

Intervening on Risk - How Diagnostic Management Stress testing Catheterization Revascularization Medical Management Maximize medical treatment Prophylaxis data is poor except for statin?

Perioperative testing -12 Lead EKG

Perioperative testing EF evaluation by Echo

Noninvasive Stress Testing. First, exercise and pharmacological stress testing have excellent negative predictive values (between 90% and 100%) but poor positive predictive values (between 6% and 67%), making them more useful for reducing risk estimates when negative (or normal) than for identifying veryhigh risk when positive. Second, compared with exercise testing, pharmacological stress tests have superior discriminative power and can be used in patients with functional limitations, the majority of patients referred for noninvasive testing. Third, dobutamine echocardiography may be preferable because of higher specificity,33 because it assesses ventricular and valvular function as well as pulmonary pressures, and because its findings may be more independent

Peroperative Stress Test

Preoperative Stress testing 2. Evaluation for restenosis post PCI

Preoperative Stress testing

Preoperative Cath

Preoperative Cath

Preoperative Cath

Preoperative Cath

Intervening on Risk - Survival of the Fittest? Morbidity Mortality ETT 1/1000 1/10,000 Cath 1/250 1/5000 PTCA 1/40 1/100 CABG 1/30 2-5/100 Total 2-5/100 2-5/100

CARP Benefit of CV revasc prior to major elective vascular surgery Screened 5859 VA patients scheduled for vasclular operations 510 eligible for the study Insuffienct Cardiac risk - 1654 Urgent/Emergent Surgery - 1025 Severe Coexisting illness - 731 Prior revasc w/o ischemia 626 Refused/Conflict - 633 NEJM 2004

CARP 510 eligible for the study 680 protocol exclusions 363 No CAD on Cath 215 CAD not amenable to revasc 54 LM disease 11 EF < 20% 8 AS 29 Refused withdrew NEJM 2004

CARP Population 74% high risk patient by current evaluation standards 28% - 3 or more CV risk factors 65% - 3 or more risk factors or 1-2 with demonstrated ischemia Nuc stress testing in 316 Mod to large defect in 226/316 NEJM 2004

CARP Revasc patients 240/258 underwent revasc 99 CABG (98 % compete revasc) and 141 PCI (62% complete revasc) 8 urgent vasc procedure, 9 refused revasc 1 CVA with cath Outcomes 4 deaths, 14 MI NEJM 2004

Vascular Surgery 225/258 CV revasc and 237/252 controls underwent elective PV procedure 33/258 revasc who did not undergo procedure 10 died, 18 declined, 5 new severe illness 15/252 control who did not undergo procedure 1 died (post urgent CABG), 9 declined, 5 new illness NEJM 2004

Vascular Surgery Postoperative outcomes Death Revasc No revasc Before 10 1 30 day 7 8 LT 70 67 NEJM 2004

Vascular Surgery Postoperative outcomes MI Revasc No revasc 30 day 26 34 NEJM 2004

Perioperative Aspirin Stopping aspirin associated with increased risk of MI in patients with CAD? 4.1% of 1236 patients admitted with ACS were related to stopping ASA Over ½ of these patients were related to perioperative cessation of aspirin Recent meta-analysis of 1930 patients asa withdrawl preceeded 10.2% of prioperative CV events Bleeding risk for continuing?????

BNP as a predictor Study evaluating cohort of patients with hx CHF, aortic stenosis or EF < 40% 44 patients, 15 with events defined as death, MI or need for IV diuretic in 30 days Mean BNP in those with events was 1300+ and those without 167 Cardiology 2008;110:266 270

BNP as a predictor Cardiology 2008;110:266 270

Lindenauer et al NEJM 2005, 353:349-361

POISE and peri-operative b-blockers 8351 subjects in 23 countries and 180 hospitals Extended release metoprolol or placebo started 2-4 hours before surgery and given 30 days Primary endpoint of CV death, MI, nonfatal arrest Lancet 371, 2008

POISE and peri-operative b-blockers Lancet 371, 2008

POISE and peri-operative b-blockers Primary endpoint hazard of 0.85 p=0.04 (244 (5.8%) vs 290 (6.9%) Mortality hazard of 1.33 p= 0.04 (129 (3.1%) vs 97 (2.3%) Stroke hazard 2.1 p=0.005 Lancet 371, 2008

POISE and peri-operative b-blockers For every 1000 subjects treated Advantages 15 fewer MI 3 fewer revasc 7 fewer episodes of clinically signifcant AF Harm 8 more deaths 5 more strokes 53 episodes of clinically significant hypotension 42 episodes of clinically significant bradycardia Lancet 371, 2008

POISE and peri-operative b-blockers Lancet 371, 2008

Dutch DECREASE trial 112 individuals with high CV risk all with inducible ischemia on stress echo Bisoprolol or placebo at lease a week and for a mean of 37 days before surgery Perioperative death or MI 3.4% vs 34% Poldermans et al NEJM 1999

Perioperative events and statins 497 patients with documented cardiac risk randomized to Fluvastatin 80mg or placebo (all received b-blocker) Median start 37 days before surgery Primary endpoint ischemia defined as transient EKG changes or troponin release Schouten NEJM 2009

Perioperative events and statins Primary endpoint Hazard favoring statin of 0.55 p= 0.01 (27 pts (10.8%) vs 47 pts (19%) CV death or MI Hazard favoring statin of 0.47 p=0.01 (12 pts (4.8%) vs 25 (10.1%) Schouten NEJM 2009

Summary For now the ACC/AHA risk guide is our best instrument Fair for predicting risk Poor for evaluating the efficacy of managing that risk Key is to find those at highest risk and consider intervening on the risk when it is clear that intervention reduces morbidity and mortality.

The obese patient Poirier et al Circulation 120; 86-95

Special considerations for the obese patient Respiratory Ventilation perfusion mismatching common Sleep apnea Occult pulmonary hypertension Pulmonary embolus Cardiac Diastolic CHF Systolic CHF Poirier et al Circulation 120; 86-95

Special considerations for the Coronary disease obese patient Use traditional risk factors to assess Incidence of sudden death may be increased (annual rate arrest or death of 1.6%) Rate of coronary events 7-15 per 1000 pts in population based studies but low in longitudinal evaluations of patients undergoing bariatric surgery Poirier et al Circulation 120; 86-95. n engl j med 361;5

DVT Special considerations for the obese patient High rate of incidence 0.4 to 1.1% Poirier et al Circulation 120; 86-95. n engl j med 361;5

The Obese patient - Algorithm Poirier et al Circulation 120; 86-95. n engl j med 361;5